CAPLIPOINT:NSE-Caplin Point Laboratories Limited (INR)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | NSE

Last Closing Price

INR 791.95

Change

0.00 (0.00)%

Market Cap

INR 60.50B

Volume

1.40M

Avg Analyst Target

INR 650.00 (-17.92%)

Avg User Target

INR
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Caplin Point Laboratories Limited develops, manufactures, markets, and exports generic pharmaceutical formulations and branded generic products in India and internationally. It provides tablets, capsules, vials, ophthalmic products, liquid orals, soft gel capsules, ointments, creams and gels, powder for injections, suppositories and ovules, dermo cosmetics, surgicals and disposables, pre-mix bag formulations, inhalers and sprays, IV infusion products, dry syrups, topicals, and other products, as well as liquid, lyophilized, and pre-filled injection syringes. The company also operates QueTenX, an e-commerce website. Caplin Point Laboratories Limited was founded in 1990 and is based in Chennai, India. Address: Ashvich Tower, Chennai, India, 600096

Company Website : http://www.caplinpoint.net

Address : Ashvich Tower, Chennai, India, 600096

Fiscal Year End : March

Currency: INR

Country : India

Technical Indicators

Beta : 0.78

52 Week High : 754.00

52 Week Low : 389.30

200 Day Moving Average : 536.85

50 Day Moving Average : 671.91

Shares Held By Insiders : 76.32%

Shares Held by Institutions : 1.55%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-07-25 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
SUNPHARMA:NSE Sun Pharmaceutical Industries ..

N/A

 INR1,667.53B 57.44 31.75
DIVISLAB:NSE Divi's Laboratories Limited

N/A

 INR1,280.40B 64.52 43.09
DRREDDY:NSE Dr. Reddy's Laboratories Limit..

N/A

 INR898.51B 52.28 22.27
CADILAHC:NSE Cadila Healthcare Limited

N/A

 INR630.62B 29.56 20.96
AUROPHARMA:NSE Aurobindo Pharma Limited

N/A

 INR564.49B 10.58 6.61
LUPIN:NSE Lupin Limited

N/A

 INR536.61B 44.23 20.35
ALKEM:NSE Alkem Laboratories Limited

N/A

 INR406.46B 25.64 18.73
LAURUSLABS:NSE Laurus Labs Limited

N/A

 INR348.25B 35.50 23.16
IPCALAB:NSE Ipca Laboratories Limited

N/A

 INR279.07B 24.41 17.04
NATCOPHARM:NSE NATCO Pharma Limited

N/A

 INR199.02B 45.18 26.80

ETFs Containing CAPLIPOINT

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 56.79% 75% C 64% D
Dividend Return 0.30% 20% F 12% F
Total Return 57.09% 75% C 64% D
Trailing 12 Months  
Capital Gain 99.48% 54% F 55% F
Dividend Return 0.48% 34% F 17% F
Total Return 99.96% 54% F 55% F
Trailing 5 Years  
Capital Gain 256.75% 85% B 88% B+
Dividend Return 3.74% 81% B- 47% F
Total Return 260.49% 85% B 87% B+
Average Annual (5 Year Horizon)  
Capital Gain 20.29% 56% F 71% C-
Dividend Return 0.37% 36% F 58% F
Total Return 20.66% 54% F 71% C-
Risk Return Profile  
Volatility (Standard Deviation) 57.11% 46% F 41% F
Risk Adjusted Return 36.18% 48% F 70% C-
Market Capitalization 60.50B 58% F 75% C
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 25.17 59% F 47% F
Price/Book Ratio 5.05 41% F 20% F
Price / Cash Flow Ratio 22.52 44% F 24% F
EV/EBITDA 15.76 58% F 43% F
Management Effectiveness  
Return on Equity 23.28% 70% C- 88% B+
Return on Invested Capital 20.98% 78% C+ 91% A-
Return on Assets 14.65% 88% B+ 95% A
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.78 55% F 70% C-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (INR)

Quarterly Financials (INR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.